We are pleased to invite investors and analysts to participate in our virtual event on Tuesday, 21 October 2025, to highlight new results from Roche's Ophthalmology pipeline including Phase III (SANDCAT/MEERKAT) vamikibart in UME data presented at the American Academy of Ophthalmology (AAO) from 18-20 October 2025, as well as Phase III (SatraGo-1/SatraGo-2) satralizumab in TED data presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS 2025) from 16-17 October 2025.
17:00 - 18:00 CEST / 16:00 - 17:00 BST
11:00 am - 12:00 pm EDT / 08:00 - 09:00 am PDT
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 16:00 CEST on the day of the event. > click here
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the webcast will be available via > ir.roche.com
*privacy notice
Best regards,
|
